These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19242379)

  • 41. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunotherapy of hematological malignancies using dendritic cells.
    Van de Velde AL; Berneman ZN; Van Tendeloo VF
    Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting CD19 with genetically modified EBV-specific human T lymphocytes.
    Roessig C; Scherer SP; Baer A; Vormoor J; Rooney CM; Brenner MK; Juergens H
    Ann Hematol; 2002; 81 Suppl 2():S42-3. PubMed ID: 12611072
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Positive selection and expansion of cytomegalovirus-specific CD4 and CD8 T cells in sealed systems: potential applications for adoptive cellular immunoreconstitution.
    Li Pira G; Ivaldi F; Tripodi G; Martinengo M; Manca F
    J Immunother; 2008 Oct; 31(8):762-70. PubMed ID: 18779743
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
    Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
    Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overcoming immunoescape mechanisms of BCL1 leukemia and induction of CD8+ T-cell-mediated BCL1-specific resistance in mice cured by targeted polymer-bound doxorubicin.
    Kovar M; Tomala J; Chmelova H; Kovar L; Mrkvan T; Joskova R; Zakostelska Z; Etrych T; Strohalm J; Ulbrich K; Sirova M; Rihova B
    Cancer Res; 2008 Dec; 68(23):9875-83. PubMed ID: 19047168
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A key regulatory role of the transcription factor NFATc2 in bronchial adenocarcinoma via CD8+ T lymphocytes.
    Maxeiner JH; Karwot R; Sauer K; Scholtes P; Boross I; Koslowski M; Türeci O; Wiewrodt R; Neurath MF; Lehr HA; Finotto S
    Cancer Res; 2009 Apr; 69(7):3069-76. PubMed ID: 19318584
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction of cross-priming of naive CD8+ T lymphocytes by recombinant bacillus Calmette-Guerin that secretes heat shock protein 70-major membrane protein-II fusion protein.
    Mukai T; Maeda Y; Tamura T; Matsuoka M; Tsukamoto Y; Makino M
    J Immunol; 2009 Nov; 183(10):6561-8. PubMed ID: 19846882
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regression of a murine gammaherpesvirus 68-positive b-cell lymphoma mediated by CD4 T lymphocytes.
    Robertson KA; Usherwood EJ; Nash AA
    J Virol; 2001 Apr; 75(7):3480-2. PubMed ID: 11238875
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.
    Corthay A; Lundin KU; Lorvik KB; Hofgaard PO; Bogen B
    Cancer Res; 2009 Jul; 69(14):5901-7. PubMed ID: 19567679
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors.
    Gao Y; Whitaker-Dowling P; Griffin JA; Barmada MA; Bergman I
    Cancer Gene Ther; 2009 Jan; 16(1):44-52. PubMed ID: 18654610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2K(d) -specific CD8+ T cells.
    Rahir G; Wathelet N; Hanoteau A; Henin C; Oldenhove G; Galuppo A; Lanaya H; Colau D; Mackay CR; Van den Eynde B; Moser M
    Int J Cancer; 2014 Jun; 134(12):2841-52. PubMed ID: 24249003
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.
    Søndergaard H; Coquet JM; Uldrich AP; McLaughlin N; Godfrey DI; Sivakumar PV; Skak K; Smyth MJ
    J Immunol; 2009 Dec; 183(11):7326-36. PubMed ID: 19915059
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.
    Riddell SR; Sommermeyer D; Berger C; Liu LS; Balakrishnan A; Salter A; Hudecek M; Maloney DG; Turtle CJ
    Cancer J; 2014; 20(2):141-4. PubMed ID: 24667960
    [TBL] [Abstract][Full Text] [Related]  

  • 55. State of the art in CAR T cell therapy for CD19+ B cell malignancies.
    Frigault MJ; Maus MV
    J Clin Invest; 2020 Apr; 130(4):1586-1594. PubMed ID: 32235098
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mycobacterium chelonae sensitisation induces CD4(+)-mediated cytotoxicity against BCG.
    Ho P; Zhang L; Wei X; Seah GT
    Eur J Immunol; 2009 Jul; 39(7):1841-9. PubMed ID: 19585510
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thymus repopulation after allogeneic reconstitution in hematological malignancies.
    Zöller M; Rajasagi M; Vitacolonna M; Luft T
    Exp Hematol; 2007 Dec; 35(12):1891-905. PubMed ID: 17920753
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rapid induction of OX40 ligand on primary T cells activated under DNA-damaging conditions.
    Kondo K; Okuma K; Tanaka R; Matsuzaki G; Ansari AA; Tanaka Y
    Hum Immunol; 2008 Sep; 69(9):533-42. PubMed ID: 18718855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of CD25-positive T cells during syngeneic pregnancy: production of stimulatory class II MHC molecules.
    Kyvelidou C; Chatzi K; Semitekolou M; Papathanassiou X; Vassiliadis S; Athanassakis I
    Scand J Immunol; 2009 Dec; 70(6):584-95. PubMed ID: 19906201
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse.
    Yakoub-Agha I; Saule P; Magro L; Cracco P; Duhamel A; Coiteux V; Bruno B; Dufossé F; Jouet JP; Dessaint JP; Labalette M
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):496-504. PubMed ID: 19285638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.